Abstract
In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis. The recombinant F1-V protein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed. After the final vaccination, the mice were challenged by 141 strain with 25–600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Meyer K F. Effectiveness of live or killed plague vaccines in man. Bull WHO, 1970, 42(5): 653–666
Williams J E, Altieri P L, Berman S, et al. Potency of killed plague vaccines prepared from avirulent Yersinia pestis. Bull WHO, 1980, 58(5): 753–756
Russell P, Eley S M, Hibbs S E, et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine, 1995, 13(16): 1551–1556
Williamson E D, Eley S M, Stagg A J, et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine, 1997, 15(10): 1079–1084
Williamson E D, Vesey P M, Gilhespy K J, et al. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol, 1999, 116(1): 107–114
Williamson E D, Eley S M, Griffin K F, et al. A new improved sub-unit vaccine for plague: The basis of protection. FEMS Immunol Med Microbiol, 1995, 12(3–4): 223–230
Leary S E C, Williamson E D, Griffin K F, et al. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun, 1995, 63(8): 2854–2858
Titball R W, Williamson E D. Vaccination against bubonic and pneumonic plague. Vaccine, 2001, 19(30): 4175–4184
Perry R D, Fetherston J D. Yersinia pestis — etiologic agent of plague. Clin Microbiol Rev, 1997, 10(1): 35–66
Andrews G P, Heath D G, Anderson G W Jr, et al. Fraction I capsular antigen (F1) purification from Yersinia pestis CO92 and an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun, 1996, 64(6): 2180–2187
Heath D G, Anderson G W Jr, Mauro J M, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine, 1998, 16(11–12): 1131–1137
Williamson E D, Sharp G J E, Eley S M, et al. Local and systemic immune response to a microencapsulated subunit vaccine for plague. Vaccine, 1996, 14(17–18): 1613–1619
Anderson G W Jr, Leary S E C, Williamson E D, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1 capsule positive and negative strains of Y. pestis. Infect Immun, 1996, 64(11): 4580–4585
Powell B S, Andrews G P, Enama J T, et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog, 2005, 21(5): 1490–1510
Williamson E D, Flick-Smith H C, LeButt C, et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun, 2005, 73(6): 3598–3608
Wang D, Huang S J, Xing L, et al. Purification and immuno-protection in BALB/c mice of recombinant F1-V fusion protein of Yersinia pestis. Prog Biochem Biophys (in Chinese), 2006, 33(3): 287–291.
Shu C L, Gao J Y, Peng H, et al. The immune reaction in mucosal and systemic immune system was induced after in tranasal immunization with bivalent Shigella vaccines. Chin J Immun (in Chinese), 2001, 17(10): 521–524
Pulendran B, Smith J L, Caspary G, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA, 1999, 96(3): 1036–1041
Jones S M, Day F, Stagg A J. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine, 2000, 19(2–3): 358–366
Chinese Pharmacopocia Commission of Biological Products Standardization. Regulations of Manufacture and Check of Plague Vaccine (Live) for Percutaneous Scarification (in Chinese). Beijing: Chemical Industry Press, 2005. 40–42
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work
Rights and permissions
About this article
Cite this article
Wang, D., Jia, N., Li, P. et al. Protection against lethal subcutaneous challenge of virulent Y. pestis strain 141 using an F1-V subunit vaccine. SCI CHINA SER C 50, 600–604 (2007). https://doi.org/10.1007/s11427-007-0071-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11427-007-0071-8